오성용 교수 연구실
article|
인용수 2
·2025
Nivolumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Korean Patients with HER2-Negative, Untreated, Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer: Subgroup Analysis of a Randomized, Multicenter, Double-Blind Phase 3 Trial (ATTRACTION-4)
Yoon‐Koo Kang, Min‐Hee Ryu, Do‐Youn Oh, Sang Cheul Oh, Sun Young Rha, Keun‐Wook Lee, Ik Joo Chung, Sung Yong Oh, Sun Jin Sym, Won Ki Kang, Jong Gwang Kim, Byoung Yong Shim, Inho Kim, Jin Young Kim, Eun‐Kee Song, Hyo Jin Lee, Seok Yun Kang, Dong‐Hoe Koo, So Yeon Oh
Cancer Research and Treatment
초록
These findings demonstrate the clinical benefit of nivolumab combined with chemotherapy (either SOX or CAPOX) for first-line treatment of gastric cancer/gastroesophageal junction cancer in Korean patients.
키워드
MedicineGastroesophageal JunctionChemotherapyPlaceboInternal medicineGastroenterologySubgroup analysisNivolumabPhases of clinical researchCancer